Sarepta Therapeutics Inc (NASDAQ:SRPT) CEO Buys $2,000,133.64 in Stock

Share on StockTwits

Sarepta Therapeutics Inc (NASDAQ:SRPT) CEO Douglas S. Ingram purchased 16,252 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were bought at an average price of $123.07 per share, for a total transaction of $2,000,133.64. Following the completion of the transaction, the chief executive officer now owns 424,405 shares of the company’s stock, valued at $52,231,523.35. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Shares of NASDAQ SRPT opened at $122.98 on Thursday. Sarepta Therapeutics Inc has a 12 month low of $95.21 and a 12 month high of $165.87. The company has a quick ratio of 11.15, a current ratio of 12.17 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of -22.52 and a beta of 2.01. The stock’s 50-day simple moving average is $145.75.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($3.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative return on equity of 56.64% and a negative net margin of 165.52%. The business had revenue of $94.67 million for the quarter, compared to analysts’ expectations of $91.05 million. During the same period in the previous year, the firm posted ($1.67) EPS. The firm’s revenue for the quarter was up 28.8% compared to the same quarter last year. As a group, analysts anticipate that Sarepta Therapeutics Inc will post -4.42 EPS for the current year.

Several brokerages have recently weighed in on SRPT. Citigroup decreased their price target on Sarepta Therapeutics from $201.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, May 16th. Evercore ISI reiterated a “buy” rating and set a $200.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, August 8th. ValuEngine cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research report on Monday, June 17th. Finally, BTIG Research set a $190.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have assigned a buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus price target of $208.29.

Hedge funds and other institutional investors have recently modified their holdings of the company. First Light Asset Management LLC bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $456,000. California State Teachers Retirement System raised its holdings in shares of Sarepta Therapeutics by 6.9% during the second quarter. California State Teachers Retirement System now owns 112,277 shares of the biotechnology company’s stock valued at $17,060,000 after acquiring an additional 7,255 shares in the last quarter. Paloma Partners Management Co bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $312,000. Vanguard Group Inc. raised its holdings in shares of Sarepta Therapeutics by 3.9% during the second quarter. Vanguard Group Inc. now owns 6,232,424 shares of the biotechnology company’s stock valued at $947,017,000 after acquiring an additional 232,752 shares in the last quarter. Finally, Ellington Management Group LLC bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $213,000. 95.57% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Article: What does cost of debt say about a company’s financial health?

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cairn Energy  PT Raised to GBX 270
Cairn Energy PT Raised to GBX 270
AstraZeneca  Price Target Raised to GBX 8,200
AstraZeneca Price Target Raised to GBX 8,200
Britvic  Upgraded to “Buy” by Jefferies Financial Group
Britvic Upgraded to “Buy” by Jefferies Financial Group
AstraZeneca  PT Set at GBX 8,500 by Bank of America
AstraZeneca PT Set at GBX 8,500 by Bank of America
Bovis Homes Group’s  “Neutral” Rating Reaffirmed at UBS Group
Bovis Homes Group’s “Neutral” Rating Reaffirmed at UBS Group
HSBC Analysts Give easyJet  a GBX 1,000 Price Target
HSBC Analysts Give easyJet a GBX 1,000 Price Target


© 2006-2019 Ticker Report